Amylyx Withdraws ALS Drug Relyvrio from Market Following Failed Trial
Amylyx Pharmaceuticals has decided to voluntarily remove its ALS drug, Relyvrio, from the market following a failed clinical trial that showed the drug's ineffectiveness in treating amyotrophic lateral sclerosis. The company will not make the drug available to new patients and plans to transition existing patients to a free drug program. This move comes after the drug's approval by the FDA in 2022 based on a single trial, which sparked controversy. Amylyx will also reduce its staff by 70 percent and continue to study the results of the failed trial to inform future ALS research while focusing on developing a drug for Wolfram syndrome.